Case Updates
D.C. Circuit affirms district court’s vacatur of HHS rule that broadly required drug manufacturers to disclose the wholesale acquisition cost of drugs and biologics in television advertisements
June 16, 2020
The court held that HHS lacked statutory authority to promulgate the rule. The U.S. Chamber filed an amicus brief supporting this outcome.
U.S. Chamber files amicus brief arguing that the Centers for Medicare and Medicaid Services lacks statutory authority to require pharmaceutical manufacturers to state the wholesale acquisition cost for drugs in TV ads
November 19, 2019
Click here to view the Chamber’s brief.
Jeffrey S. Bucholtz, Joel McElvain, and I. Cason Hewgley IV of King & Spalding LLP served as co-counsel for the U.S. Chamber of Commerce on behalf of the U.S. Chamber Litigation Center.
Case Documents
- District Court Opinion -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Government Opening Brief -- Merck & Co. v. HHS (D.C. Circuit).pdf
- U.S. Chamber Amicus Brief -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Appellant Brief -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Goldwater Institute Amicus Brief -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Appellee Brief -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Appellant Final Reply Brief -- Merck & Co. v HHS (D.C. Circuit).pdf
- Letter -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Response -- Merck & Co. v. HHS (D.C. Circuit).pdf
- Opinion -- Merck & Co. v. HHS (D.C. Circuit).pdf